• Sodium Ascorbate in Cancer Research: Evidence Limits

  2026-10-13

  Sodium Ascorbate is described as a mineral salt of ascorbic acid with reported effects on tumor-cell proliferation, motility, and reactive oxygen species. However, the supplied evidence is primarily a supplier summary rather than an independently assessable primary study, so the findings remain preliminary and model-specific.

• Astrocytic GAT-3 Links GABA to Dentate Gyrus Memory

  2026-10-13

  Shen and colleagues investigated how GABAergic activity regulates synaptic transmission in the entorhinal cortex–dentate gyrus circuit. Their multimodal evidence supports a model in which astrocytic GAT-3 engages calcium signaling, influences excitatory transmission through GluN2B-containing NMDA receptors, and contributes to contextual fear-memory formation. The findings are circuit- and model-specific, and the supplied summary does not provide enough methodological or statistical detail to judge effect sizes, selectivity, or broader clinical relevance.

• CGP 55845 Hydrochloride and GABA Signaling

  2026-10-12

  CGP 55845 hydrochloride is described by its supplier as a selective GABAB receptor antagonist, but the supplied dentate-gyrus study investigated astrocytic GAT-3 rather than this compound. The findings support a role for astrocyte–neuron signaling in synaptic transmission and memory, while leaving the compound’s relevance to that pathway unresolved.

• KDM4A as a Preclinical Vulnerability in Mesothelioma

  2026-10-12

  A 2021 study links elevated KDM4A activity to malignant pleural mesothelioma growth in cellular and xenograft models. The findings support KDM4A as a biologically relevant preclinical vulnerability, while remaining insufficient to establish clinical efficacy, patient selection criteria, or applicability beyond the tested models.

• SCUBE3 Targeting Rewires Cancer Signaling and Immunity

  2026-10-11

  Singh and colleagues identify secretory SCUBE3 as a multifunctional driver of tumor survival, therapy resistance, oncogenic signaling, and immune suppression. Their preclinical findings support extracellular SCUBE3 neutralization as a potential strategy, while also highlighting the need to validate pathway dependence, immune effects, and therapeutic relevance across cancer models.

• Lambda Protein Phosphatase in BMAL1 Studies

  2026-10-10

  A source-grounded overview of how λ-PPase can inform BMAL1 phosphorylation research, what the 2026 phase-separation study demonstrates, and where enzyme-based evidence remains limited.

• Pseudo-UTP and Pseudouridine in RNA Research

  2026-10-09

  Pseudo-UTP is a pseudouridine-containing nucleotide of interest in RNA synthesis, innate immune recognition, and translational research. Current evidence supports important biological questions but does not justify treating supplier claims about stability, translation, or reduced immunogenicity as universal outcomes across RNA designs, cell types, or clinical applications.

• DNA Nanosystems for mRNA Delivery: Review Insights

  2026-10-09

  The review by Tang, Xiao, and Yang examines how programmable DNA architectures could address persistent barriers in mRNA delivery. Its central contribution is a framework comparing branched DNA nanohydrogels, nucleic acid origami, and polymer–DNA hybrids by cargo handling, structural control, release behavior, and biomedical relevance, while emphasizing that most evidence remains preclinical and system-dependent.

• DRP1, Mitochondrial Fission, and Hyperoxia in ATII Cells

  2026-10-08

  Sun et al. connect hyperoxia in alveolar type II cells with increased DRP1-associated mitochondrial fission and a shift toward aerobic glycolysis. Their tissue, primary-cell, and pharmacological evidence supports a mechanistic relationship relevant to bronchopulmonary dysplasia, while the model remains preclinical and does not establish clinical efficacy.

• Biotin-16-UTP Product Overview

  2026-10-08

  Biotin-16-UTP (SKU B8154) is a supplier-described biotin-labeled uridine triphosphate analog for conceptual use in in vitro transcription RNA labeling. No matched paper evidence was provided, so performance, compatibility, and assay outcomes cannot be independently assessed.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-10-07

  The 2024 ACS Applied Materials & Interfaces study identifies a mechanistic link between lithium exposure, Rab11a-dependent exosomal Wnt10a secretion, and activation of the Wnt/β-catenin signaling pathway in bone mesenchymal stem cells. Its findings suggest that lithium-engineered exosomes and GelMA-based delivery systems may improve osteogenic activity, while also highlighting important limits when translating pathway observations into therapeutic claims.

• Mubritinib (TAK 165): Mechanism and Evidence

  2026-10-07

  Mubritinib, also known as TAK 165, is best interpreted as a mitochondrial complex I inhibitor with context-dependent activity in AML and KSHV-positive PEL models. The available dossier supports mechanistic and preclinical research use, but it does not establish clinical efficacy or provide enough assay detail for direct protocol replication.

• Microbiota–AhR Axis in Ulcerative Colitis Repair

  2026-10-06

  Li et al. describe a microbiota–tryptophan metabolite–AhR–intestinal stem cell axis that may explain how Huangqin decoction supports mucosal repair in a mouse model of ulcerative colitis. The study combines microbiome, metabolite, pathway, and epithelial differentiation evidence, while leaving important questions about cell-specific causality and translation to human disease.

• Homoharringtonine and SARS-CoV-2: Study Evidence

  2026-10-06

  The reference study evaluates homoharringtonine across cell-based assays, animal models, and two early human cohorts, reporting inhibition of multiple coronaviruses and rapid SARS-CoV-2 clearance signals. Its main contribution is a cross-scale translational case for further investigation, although small, non-randomized patient groups and limited safety data prevent the findings from establishing clinical efficacy.

• Protease Inhibitor Cocktail: Product Overview

  2026-10-05

  K4001 is a supplier-described 50X DMSO protease inhibitor blend for conceptual protein degradation prevention during extraction, with no matched paper evidence available for product-specific performance.

8179 records 1/546 page Next 12345 下5页 Last page